Comparison of Floseal® and Tranexamic Acid for Bleeding Control after Total Knee Arthroplasty: a Prospective Randomized Study

Camilo Partezani Helito, Marcelo Batista Bonadio, Marcel Faraco Sobrado, Pedro Nogueira Giglio, José Ricardo Pécora, Gilberto Luis Camanho, Marco Kawamura Demange, Camilo Partezani Helito, Marcelo Batista Bonadio, Marcel Faraco Sobrado, Pedro Nogueira Giglio, José Ricardo Pécora, Gilberto Luis Camanho, Marco Kawamura Demange

Abstract

Objective: Tranexamic acid (TXA) and the hemostatic agent Floseal® have already been used to minimize bleeding during total knee arthroplasty (TKA).

Methods: We conducted a prospective, randomized study of 90 patients with indications for TKA. Following inclusion, the participants were randomly allocated in blocks to the following 3 groups: control, Floseal® and TXA. Bleeding parameters, including decreases in hemoglobin (Hb), drain output, number of blood transfusions and complications, were assessed. ClinicalTrials.gov: NCT02152917.

Results: The mean decrease in Hb was highest in the control group (4.81±1.09 g/dL), followed by the Floseal® (3.5±1.03 g/dL) and TXA (3.03±1.2 g/dL) groups. The Floseal® and TXA groups did not differ, and both performed better than the control group. The mean total drain output was 901.3±695.7 mL in the control group, 546.5±543.5 mL in the TXA group and 331.2±278.7 mL in the Floseal® group. Both TXA and Floseal® had significantly less output than the control group, and Floseal® had significantly less output than TXA. The number of blood transfusions was very small in all 3 groups.

Conclusion: The use of TXA or Floseal® was associated with less blood loss than that of the control group among patients undergoing primary TKA, as measured both directly (intraoperative bleeding + drainage) and on the basis of a decrease in Hb, without differences in the rate of complications. TXA and Floseal® showed similar decreases in Hb and total measured blood loss, but the drain output was smaller in the Floseal® group.

Conflict of interest statement

No potential conflict of interest was reported.

Figures

Figure 1. Application of Floseal ® to…
Figure 1. Application of Floseal® to the surgical wound.

References

    1. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89(4):780–5. doi: 10.2106/JBJS.F.00222.
    1. Losina E, Thornhill TS, Rome BN, Wright J, Katz JN. The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. J Bone Joint Surg Am. 2012;94(3):201–7. doi: 10.2106/JBJS.J.01958.
    1. Petaja J, Myllynen P, Myllyla G, Vahtera E. Fibrinolysis after application of a pneumatic tourniquet. Acta Chir Scand. 1987;153(11-12):647–51.
    1. Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood. 1987;70(5):1645–53. doi: 10.1182/blood.V70.5.1645.1645.
    1. Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis. 1994;5(4):537–42.
    1. Hiippala ST, Strid LJ, Wennerstrand MI, Arvela JV, Niemela HM, Mantyla SK, et al. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg. 1997;84(4):839–44. doi: 10.1213/00000539-199704000-00026.
    1. Whiting DR, Gillette BP, Duncan C, Smith H, Pagnano MW, Sierra RJ. Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. Clin Orthop Relat Res. 2014;472(1):66–72. doi: 10.1007/s11999-013-3134-0.
    1. Reuthebuch O, Lachat ML, Vogt P, Schurr U, Turina M. FloSeal: a new hemostyptic agent in peripheral vascular surgery. Vasa. 2000;29(3):204–6. doi: 10.1024/0301-1526.29.3.204.
    1. Richter F, Schnorr D, Deger S, Trk I, Roigas J, Wille A, et al. Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal) Urology. 2003;61(1):73–7. doi: 10.1016/S0090-4295(02)02143-X.
    1. Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in children undergoing adenoidectomy. Otolaryngol Head Neck Surg. 2004;131(5):601–5. doi: 10.1016/j.otohns.2004.05.025.
    1. Nasso G, Piancone F, Bonifazi R, Romano V, Visicchio G, De Filippo CM, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88(5):1520–6. doi: 10.1016/j.athoracsur.2009.07.014.
    1. Ellegala DB, Maartens NF, Laws ER., Jr Use of FloSeal hemostatic sealant in transsphenoidal pituitary surgery: technical note. Neurosurgery. 2002;51(2):513–5. doi: 10.1097/00006123-200208000-00041.
    1. Dogulu F, Durdag E, Cemil B, Kurt G, Ozgun G. The role of FloSeal in reducing epidural fibrosis in a rat laminectomy model. Neurol Neurochir Pol. 2009;43(4):346–51.
    1. Miyamoto K, Masuda K, Inoue N, Okuma M, Muehleman C, An HS. Anti-adhesion properties of a thrombin-based hemostatic gelatin in a canine laminectomy model: a biomechanical, biochemical, and histologic study. Spine. 2006;31(4):E91–7. doi: 10.1097/01.brs.0000199902.80607.ce.
    1. García Aríz M, Pérez-Carrasquillo O, Zierenberg CE, Cheleuitte J, Guerra JA, Santiago-Borrero PJ. Hemostatic matrix application after open synovectomy in a hemophilic patient. Am J Orthop. 2012;41(4):179–81.
    1. Kim HJ, Fraser MR, Kahn B, Lyman S, Figgie MP. The efficacy of a thrombin-based hemostatic agent in unilateral total knee arthroplasty: a randomized controlled trial. J Bone Joint Surg Am. 2012;94(13):1160–5. doi: 10.2106/JBJS.K.00531.
    1. Helito CP, Gobbi RG, Castrillon LM, Hinkel BB, Pécora JR, Camanho GL. Comparação entre Floseal® e eletrocauterio na hemostasia após artroplastia total do joelho. Acta Ortop Bras. 2013;21(6):320–2. doi: 10.1590/S1413-78522013000600004.
    1. Wang C, Han Z, Zhang T, Ma JX, Jiang X, Wang Y, et al. The efficacy of a thrombin-based hemostatic agent in primary total knee arthroplasty: a meta-analysis. J Orthop Surg Res. 2014;9:90. doi: 10.1186/s13018-014-0090-7.
    1. Helito CP, Junqueira JJ, Gobbi RG, Angelini FJ, Rezende MU, Tirico LE, et al. Effect of postoperative use of nasal oxygen catheter supplementation in wound healing following total knee arthroplasty. Clinics. 2014;69(11):735–9. doi: 10.6061/clinics/2014(11)05.
    1. Livingston EH, Cassidy L. Statistical power and estimation of the number of required subjects for a study based on the t-test: a surgeon’s primer. J Surg Res. 2005;126(2):149–59. doi: 10.1016/j.jss.2004.12.013.
    1. Charoencholvanich K, Siriwattanasakul P. Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. Clin Orthop Relat Res. 2011;469(10):2874–80. doi: 10.1007/s11999-011-1874-2.
    1. Kelley TC, Tucker KK, Adams MJ, Dalury DF. Use of tranexamic acid results in decreased blood loss and decreased transfusions in patients undergoing staged bilateral total knee arthroplasty. Transfusion. 2014;54(1):26–30. doi: 10.1111/trf.12167.
    1. Kim TK, Chang CB, Kang YG, Seo ES, Lee JH, Yun JH, et al. Clinical value of tranexamic acid in unilateral and simultaneous bilateral TKAs under a contemporary blood-saving protocol: a randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2014;22(8):1870–8. doi: 10.1007/s00167-013-2492-1.
    1. Cid J, Lozano M. Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials. Transfusion. 2005;45(8):1302–7. doi: 10.1111/j.1537-2995.2005.00204.x.
    1. Zhang H, Chen J, Chen F, Que W. The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2012;20(9):1742–52. doi: 10.1007/s00167-011-1754-z.
    1. Romanò CL, Monti L, Logoluso N, Romanò D, Drago L. Does a thrombin-based topical haemostatic agent reduce blood loss and transfusion requirements after total knee revision surgery? A randomized, controlled trial. Knee Surg Sports Traumatol Arthrosc. 2015;23(11):3337–42. doi: 10.1007/s00167-014-3153-8.
    1. Velyvis JH. Gelatin matrix use reduces postoperative bleeding after total knee arthroplasty. Orthopedics. 2015;38(2):e118–23. doi: 10.3928/01477447-20150204-59.
    1. Comadoll JL, Comadoll S, Hutchcraft A, Krishnan S, Farrell K, Kreuwel HT, et al. Comparison of hemostatic matrix and standard hemostasis in patients undergoing primary TKA. Orthopedics. 2012;35(6):e785–93. doi: 10.3928/01477447-20120525-14.
    1. Di Francesco A, Flamini S, Fiori F, Mastri F. Hemostatic matrix effects on blood loss after total knee arthroplasty: A randomized controlled trial. Indian J Orthop. 2013;47(5):474–81. doi: 10.4103/0019-5413.118203.
    1. Suarez JC, Slotkin EM, Alvarez AM, Szubski CR, Barsoum WK, Patel PD. Prospective, randomized trial to evaluate efficacy of a thrombin-based hemostatic agent in total knee arthroplasty. J Arthroplasty. 2014;29(10):1950–5. doi: 10.1016/j.arth.2014.05.025.
    1. Schwab PE, Thienpont E. Use of a haemostatic matrix (FloSeal®) does not reduce blood loss in minimally invasive total knee arthroplasty performed under continued aspirin. Blood Transfus. 2016;14(2):134–9. doi: 10.2450/2015.0023-15.
    1. Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials. Knee. 2014;21(6):987–93. doi: 10.1016/j.knee.2014.09.010.
    1. Wang S, Gao X, An Y. Topical versus intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. Int Orthop. 2017;41(4):739–48. doi: 10.1007/s00264-016-3296-y.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel